ntimicrobial resistance (AMR) continues to expand, raising the risk of a future public health crisis. Numerous conferences have been organised to address the scientific challenges of AMR, such as the need to engineer novel antibiotics. However, science in isolation will not suffice.

This symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem will help design a better legal toolkit to promote antimicrobial innovation and limit the impact of resistance on global health.

The CeBIL Symposium is organised by the Cambridge Centre for Law, Medicine and Life Sciences, the Center for Advanced Studies in Biomedical Innovation Law at the University of Copenhagen, and the CeBIL International Collaboration including partners; such as CARB-X, Boston University SIDR, and PORTAL at Harvard Medical School. The Symposium is generously supported by the Novo Nordisk Foundation, the Cambridge Academy for Therapeutic Sciences (CATS), and the Cambridge Infectious Disease Interdisciplinary Research Centre.

Held at the University of Cambridge, an international hub for legal and scientific expertise, we hope the event will mobilise legal, economic, business, medical and scientific experts – early, mid, and late career – who recognise the need to work together to avert the AMR crisis.